Medicine and HealthNature Communications
Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β
U. Hommel, K. Hurth, et al.
Explore groundbreaking research by Ulrich Hommel and colleagues revealing a low-molecular-weight antagonist for human interleukin-1β. This compound demonstrates potential therapeutic benefits by effectively blocking hIL-1β's interaction with its receptor, offering hope for new treatments. Discover the allosteric mechanisms at play in this innovative study.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Chemistry
Accelerating the discovery of active and selective CO2RR catalysts using a high-throughput virtual screening strategy
D. H. Mok, H. Lee, et al.
Medicine and Health
Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia
M. E. Layton, J. C. Kern, et al.
Medicine and Health
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
P. Eijsvogel, P. Misra, et al.
Medicine and Health
A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
H. Ma, X. Zhang, et al.
